Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
|Articles|October 15, 2012
Screening for those at high risk for T2DM does not reduce mortality within 10 years, study finds
Screening patients who are at high risk for diabetes does not reduce their all-cause, cardiovascular, or diabetes-related mortality within 10 years, according to a study published Oct. 4 in The Lancet
Advertisement
Advertisement
Related to this article
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
2
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
3
American Pharmacists Month: Pharmacy Deserts Growing in US Despite Rising Awareness
4
Future IRA Drug Negotiations Expected to Compound Pharmacy Burden
5